Expression of metallothionein-1 and metallothionein-2 as a prognostic marker in hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 9, 2013, Pages 1565-1572

  Park, Yangsoon ^a   Yu, Eunsil ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Hepatocellular carcinoma; Immunohistochemistry; Metallothionein; Tissue microarray method

Indexed keywords

METALLOTHIONEIN I; METALLOTHIONEIN II;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; FEMALE; HOMEOSTASIS; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; TUMOR INVASION;

HEPATOCELLULAR CARCINOMA; IMMUNOHISTOCHEMISTRY; METALLOTHIONEIN; TISSUE MICROARRAY METHOD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CELL NUCLEUS; CYTOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER; LIVER NEOPLASMS; MALE; METALLOTHIONEIN; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM PROTEINS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84897584134     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12261     Document Type: Article

References (47)

1. Miles AT, Hawksworth GM, Beattie JH, Rodilla V. Induction, regulation, degradation, and biological significance of mammalian metallothioneins. Crit. Rev. Biochem. Mol. Biol. 2000; 35: 35-70.
2. Thirumoorthy N, Manisenthil Kumar KT, Shyam Sundar A, Panayappan L, Chatterjee M. Metallothionein: an overview. World J. Gastroenterol. 2007; 13: 993-996.
3. Pedersen MØ, Larsen A, Stoltenberg M, Penkowa M. The role of metallothionein in oncogenesis and cancer prognosis. Prog. Histochem. Cytochem. 2009; 44: 29-64.
4. Cai L, Satoh M, Tohyama C, Cherian MG. Metallothionein in radiation exposure: its induction and protective role. Toxicology 1999; 132: 85-98.
5. Theocharis SE, Margeli AP, Klijanienko JT, Kouraklis GP. Metallothionein expression in human neoplasia. Histopathology 2004; 45: 103-118.
6. Yap X, Tan HY, Huang J etal. Over-expression of metallothionein predicts chemoresistance in breast cancer. J. Pathol. 2009; 217: 563-570.
7. Jin R, Huang J, Tan PH, Bay BH. Clinicopathological significance of metallothioneins in breast cancer. Pathol. Oncol. Res. 2004; 10: 74-79.
8. Joseph MG, Banerjee D, Kocha W, Feld R, Stitt LW, Cherian MG. Metallothionein expression in patients with small cell carcinoma of the lung: correlation with other molecular markers and clinical outcome. Cancer 2001; 92: 836-842.
9. McCluggage WG, Maxwell P, Hamilton PW, Jasani B. High metallothionein expression is associated with features predictive of aggressive behaviour in endometrial carcinoma. Histopathology 1999; 34: 51-55.
10. Hengstler JG, Pilch H, Schmidt M etal. Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis. Int. J. Cancer 2001; 95: 121-127.
11. Mitropoulos D, Kyroudi-Voulgari A, Theocharis S etal. Prognostic significance of metallothionein expression in renal cell carcinoma. World J. Surg. Oncol. 2005; 3: 5.
12. Tuzel E, Kirkali Z, Yorukoglu K, Mungan MU, Sade M. Metallothionein expression in renal cell carcinoma: subcellular localization and prognostic significance. J. Urol. 2001; 165: 1710-1713.
13. Yamasaki Y, Smith C, Weisz D etal. Metallothionein expression as prognostic factor for transitional cell carcinoma of bladder. Urology 2006; 67: 530-535.
14. Satoh M, Cherian MG, Imura N, Shimizu H. Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis. Cancer Res. 1994; 54: 5255-5257.
15. Moussa M, Kloth D, Peers G, Cherian MG, Frei JV, Chin JL. Metallothionein expression in prostatic carcinoma: correlation with Gleason grade, pathologic stage, DNA content and serum level of prostate-specific antigen. Clin. Invest. Med. 1997; 20: 371-380.
16. Eid H, Institoris E, Bodrogi I, Bak M. [Metallothionein expression as a marker of therapeutic sensitivity in the early stages of testicular cancer]. Orv. Hetil. 1997; 138: 135-139.
17. Endo T, Yoshikawa M, Ebara M etal. Immunohistochemical metallothionein expression in hepatocellular carcinoma: relation to tumor progression and chemoresistance to platinum agents. J. Gastroenterol. 2004; 39: 1196-1201.
18. Tao X, Zheng JM, Xu AM, Chen XF, Zhang SH. Downregulated expression of metallothionein and its clinicopathological significance in hepatocellular carcinoma. Hepatol. Res. 2007; 37: 820-827.
19. Cherian MG. The significance of the nuclear and cytoplasmic localization of metallothionein in human liver and tumor cells. Environ. Health Perspect. 1994; 102 (Suppl. 3): 131-135.
20. Cherian MG, Apostolova MD. Nuclear localization of metallothionein during cell proliferation and differentiation. Cell Mol. Biol. (Noisy-le-grand) 2000; 46: 347-356.
21. Furuta K, Sato S, Yamauchi T, Ozawa T, Harada M, Kakumu S. Intrahepatic gene expression profiles in chronic hepatitis B and autoimmune liver disease. J. Gastroenterol. 2008; 43: 866-874.
22. Huang GW, Yang LY. Metallothionein expression in hepatocellular carcinoma. World J. Gastroenterol. 2002; 8: 650-653.
23. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Tortti A III. AJCC Cancer Staging Manual. New York: Springer, 2010; 191-199.
24. Moffatt P, Denizeau F. Metallothionein in physiological and physiopathological processes. Drug Metab. Rev. 1997; 29: 261-307.
25. Jacob ST, Majumder S, Ghoshal K. Suppression of metallothionein-I/II expression and its probable molecular mechanisms. Environ. Health Perspect. 2002; 110 (Suppl. 5): 827-830.
26. Lu DD, Chen YC, Zhang XR, Cao XR, Jiang HY, Yao L. The relationship between metallothionein-1F (MT1F) gene and hepatocellular carcinoma. Yale J. Biol. Med. 2003; 76: 55-62.
27. Kanda M, Nomoto S, Okamura Y etal. Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int. J. Oncol. 2009; 35: 477-483.
28. Iizuka N, Oka M, Yamada-Okabe H etal. Self-organizing-map-based molecular signature representing the development of hepatocellular carcinoma. FEBS Lett. 2005; 579: 1089-1100.
29. Ghoshal K, Majumder S, Li Z, Dong X, Jacob ST. Suppression of metallothionein gene expression in a rat hepatoma because of promoter-specific DNA methylation. J. Biol. Chem. 2000; 275: 539-547.
30. Sakamoto LH, DE Camargo B, Cajaiba M, Soares FA, Vettore AL. MT1G hypermethylation: a potential prognostic marker for hepatoblastoma. Pediatr. Res. 2010; 67: 387-393.
31. Henrique R, Jeronimo C, Hoque MO etal. MT1G hypermethylation is associated with higher tumor stage in prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2005; 14: 1274-1278.
32. Huang Y, de la Chapelle A, Pellegata NS. Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. Int. J. Cancer 2003; 104: 735-744.
33. Ferrario C, Lavagni P, Gariboldi M etal. Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma. Lab. Invest. 2008; 88: 474-481.
34. Roth MJ, Abnet CC, Hu N etal. p16, MGMT, RARbeta2, CLDN3, CRBP and MT1G gene methylation in esophageal squamous cell carcinoma and its precursor lesions. Oncol. Rep. 2006; 15: 1591-1597.
35. Datta J, Majumder S, Kutay H etal. Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade. Cancer Res. 2007; 67: 2736-2746.
36. Tsujikawa K, Imai T, Kakutani M etal. Localization of metallothionein in nuclei of growing primary cultured adult rat hepatocytes. FEBS Lett. 1991; 283: 239-242.
37. Tsujikawa K, Suzuki N, Sagawa K etal. Induction and subcellular localization of metallothionein in regenerating rat liver. Eur. J. Cell Biol. 1994; 63: 240-246.
38. Ogra Y, Suzuki KT. Nuclear trafficking of metallothionein: possible mechanisms and current knowledge. Cell Mol. Biol. (Noisy-le-grand) 2000; 46: 357-365.
39. Woo ES, Lazo JS. Nucleocytoplasmic functionality of metallothionein. Cancer Res. 1997; 57: 4236-4241.
40. Bosman FT; World Health O, International Agency for Research on C. WHO Classification of Tumours of the Digestive System. Lyon: International Agency for Research on Cancer, 2010.
41. Hung HH, Lei HJ, Chau GY etal. Milan criteria, multi-nodularity, and microvascular invasion predict the recurrence patterns of hepatocellular carcinoma after resection. J. Gastrointest. Surg. 2012; 17: 702-711.
42. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Tortti A III. AJCC Cancer Staging Manual. New York: Springer, 2010.
43. Jung ES, Kang YK, Cho MY etal. Update on the proposal for creating a guideline for cancer registration of the gastrointestinal tumors (I-2). Korean J. Pathol. 2012; 46: 443-453.
44. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988; 241: 1813-1815.
45. Kondo Y, Kuo SM, Watkins SC, Lazo JS. Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines. Cancer Res. 1995; 55: 474-477.
46. Kikuchi Y, Hirata J, Yamamoto K etal. Altered expression of gamma-glutamylcysteine synthetase, metallothionein and topoisomerase I or II during acquisition of drug resistance to cisplatin in human ovarian cancer cells. Jpn J. Cancer Res. 1997; 88: 213-217.
47. Surowiak P, Materna V, Maciejczyk A etal. Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome. Virchows Arch. 2007; 450: 279-285.